Medical treatment of neuroendocrine tumors

E. Bajetta, M. Di Bartolomeo, N. Zilembo, A. M. Bochicchio

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Tumors of the neuroendocrine system are characterized by amine precursor uptake and decarboxylation, and they represent a heterogeneous group of carcinomas including carcinoids, islet cell carcinomas of the pancreas, medullary thyroid carcinomas and Merkel cell carcinomas. Their similar cytochemical and ultrastructural properties sustain the hypothesis of a common embryologic origin within the neural crest. Many of these tumors grow slowly, and reducing tumor burden represents the treatment of choice. However, when surgery is not feasible, medical treatment has to be considered. Therapeutic approaches in metastatic disease often do not consider the different biologic behaviors of these neoplasms. Moreover, efficacy of the treatment is associated with lack of a clear definition of the type of response: objective, symptomatic or biochemical. Methods: In this review we have analyzed the different medical approaches used in the treatment of neuroendocrine tumors in an attempt to define their precise role in the different neoplasms. Results: In carcinoid tumors, immunotherapy and the somatostatin analogue can be efficaciously used for the control of carcinoid syndrome. For inhibition of tumor growth, chemotherapy should be used only in patients with rapidly progressive disease, and the results are still unsatisfactory. Conclusions: Although all these tumors appear to have similar cytochemical properties, the responsiveness of the various neoplasms is very different. In the future, a specific treatment modality and a clear definition of the type of response (objective, symptomatic or biochemical) need to be defined for each type of neuroendocrine tumor.

Original languageEnglish
Pages (from-to)380-388
Number of pages9
JournalTumori
Volume79
Issue number6
Publication statusPublished - 1993

Fingerprint

Neuroendocrine Tumors
Carcinoid Tumor
Neoplasms
Therapeutics
Islet Cell Carcinoma
Merkel Cell Carcinoma
Neurosecretory Systems
Decarboxylation
Neural Crest
Somatostatin
Tumor Burden
Immunotherapy
Amines
Pancreas
Carcinoma
Drug Therapy
Growth

Keywords

  • chemotherapy
  • hormonotherapy
  • immunotherapy
  • neuroendocrine tumors

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bajetta, E., Di Bartolomeo, M., Zilembo, N., & Bochicchio, A. M. (1993). Medical treatment of neuroendocrine tumors. Tumori, 79(6), 380-388.

Medical treatment of neuroendocrine tumors. / Bajetta, E.; Di Bartolomeo, M.; Zilembo, N.; Bochicchio, A. M.

In: Tumori, Vol. 79, No. 6, 1993, p. 380-388.

Research output: Contribution to journalArticle

Bajetta, E, Di Bartolomeo, M, Zilembo, N & Bochicchio, AM 1993, 'Medical treatment of neuroendocrine tumors', Tumori, vol. 79, no. 6, pp. 380-388.
Bajetta, E. ; Di Bartolomeo, M. ; Zilembo, N. ; Bochicchio, A. M. / Medical treatment of neuroendocrine tumors. In: Tumori. 1993 ; Vol. 79, No. 6. pp. 380-388.
@article{5cbfcf26574d42ee8e40ab5954bc0848,
title = "Medical treatment of neuroendocrine tumors",
abstract = "Background: Tumors of the neuroendocrine system are characterized by amine precursor uptake and decarboxylation, and they represent a heterogeneous group of carcinomas including carcinoids, islet cell carcinomas of the pancreas, medullary thyroid carcinomas and Merkel cell carcinomas. Their similar cytochemical and ultrastructural properties sustain the hypothesis of a common embryologic origin within the neural crest. Many of these tumors grow slowly, and reducing tumor burden represents the treatment of choice. However, when surgery is not feasible, medical treatment has to be considered. Therapeutic approaches in metastatic disease often do not consider the different biologic behaviors of these neoplasms. Moreover, efficacy of the treatment is associated with lack of a clear definition of the type of response: objective, symptomatic or biochemical. Methods: In this review we have analyzed the different medical approaches used in the treatment of neuroendocrine tumors in an attempt to define their precise role in the different neoplasms. Results: In carcinoid tumors, immunotherapy and the somatostatin analogue can be efficaciously used for the control of carcinoid syndrome. For inhibition of tumor growth, chemotherapy should be used only in patients with rapidly progressive disease, and the results are still unsatisfactory. Conclusions: Although all these tumors appear to have similar cytochemical properties, the responsiveness of the various neoplasms is very different. In the future, a specific treatment modality and a clear definition of the type of response (objective, symptomatic or biochemical) need to be defined for each type of neuroendocrine tumor.",
keywords = "chemotherapy, hormonotherapy, immunotherapy, neuroendocrine tumors",
author = "E. Bajetta and {Di Bartolomeo}, M. and N. Zilembo and Bochicchio, {A. M.}",
year = "1993",
language = "English",
volume = "79",
pages = "380--388",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Medical treatment of neuroendocrine tumors

AU - Bajetta, E.

AU - Di Bartolomeo, M.

AU - Zilembo, N.

AU - Bochicchio, A. M.

PY - 1993

Y1 - 1993

N2 - Background: Tumors of the neuroendocrine system are characterized by amine precursor uptake and decarboxylation, and they represent a heterogeneous group of carcinomas including carcinoids, islet cell carcinomas of the pancreas, medullary thyroid carcinomas and Merkel cell carcinomas. Their similar cytochemical and ultrastructural properties sustain the hypothesis of a common embryologic origin within the neural crest. Many of these tumors grow slowly, and reducing tumor burden represents the treatment of choice. However, when surgery is not feasible, medical treatment has to be considered. Therapeutic approaches in metastatic disease often do not consider the different biologic behaviors of these neoplasms. Moreover, efficacy of the treatment is associated with lack of a clear definition of the type of response: objective, symptomatic or biochemical. Methods: In this review we have analyzed the different medical approaches used in the treatment of neuroendocrine tumors in an attempt to define their precise role in the different neoplasms. Results: In carcinoid tumors, immunotherapy and the somatostatin analogue can be efficaciously used for the control of carcinoid syndrome. For inhibition of tumor growth, chemotherapy should be used only in patients with rapidly progressive disease, and the results are still unsatisfactory. Conclusions: Although all these tumors appear to have similar cytochemical properties, the responsiveness of the various neoplasms is very different. In the future, a specific treatment modality and a clear definition of the type of response (objective, symptomatic or biochemical) need to be defined for each type of neuroendocrine tumor.

AB - Background: Tumors of the neuroendocrine system are characterized by amine precursor uptake and decarboxylation, and they represent a heterogeneous group of carcinomas including carcinoids, islet cell carcinomas of the pancreas, medullary thyroid carcinomas and Merkel cell carcinomas. Their similar cytochemical and ultrastructural properties sustain the hypothesis of a common embryologic origin within the neural crest. Many of these tumors grow slowly, and reducing tumor burden represents the treatment of choice. However, when surgery is not feasible, medical treatment has to be considered. Therapeutic approaches in metastatic disease often do not consider the different biologic behaviors of these neoplasms. Moreover, efficacy of the treatment is associated with lack of a clear definition of the type of response: objective, symptomatic or biochemical. Methods: In this review we have analyzed the different medical approaches used in the treatment of neuroendocrine tumors in an attempt to define their precise role in the different neoplasms. Results: In carcinoid tumors, immunotherapy and the somatostatin analogue can be efficaciously used for the control of carcinoid syndrome. For inhibition of tumor growth, chemotherapy should be used only in patients with rapidly progressive disease, and the results are still unsatisfactory. Conclusions: Although all these tumors appear to have similar cytochemical properties, the responsiveness of the various neoplasms is very different. In the future, a specific treatment modality and a clear definition of the type of response (objective, symptomatic or biochemical) need to be defined for each type of neuroendocrine tumor.

KW - chemotherapy

KW - hormonotherapy

KW - immunotherapy

KW - neuroendocrine tumors

UR - http://www.scopus.com/inward/record.url?scp=0027842762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027842762&partnerID=8YFLogxK

M3 - Article

C2 - 8171735

AN - SCOPUS:0027842762

VL - 79

SP - 380

EP - 388

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -